Skip to main content
Journal cover image

Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.

Publication ,  Journal Article
Henson, JB; Simon, TG; Kaplan, A; Osganian, S; Masia, R; Corey, KE
Published in: Alimentary pharmacology & therapeutics
April 2020

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiovascular disease. It is not well understood, however, which individuals with NAFLD are at highest risk for cardiovascular disease.To determine the factors associated with incident cardiovascular events in a prospective cohort of individuals with biopsy-proven NAFLD without pre-existing cardiovascular disease.From 2011 to 2018, adults with biopsy-proven NAFLD without cardiovascular disease were enrolled in a tissue repository and were followed prospectively to the first recorded date of incident cardiovascular disease, death or the end of follow-up (11/1/2018). Competing risks analysis was performed to identify predictors of incident cardiovascular disease.After a median follow-up time of 5.2 years, 26/285 (9.1%) individuals experienced an incident cardiovascular event. Advanced fibrosis (stage 3-4) on biopsy was a significant predictor of incident cardiovascular disease, and this persisted on multivariable analysis (SHR 2.86, 95% CI 1.36-6.04) after considering relevant covariates, including cardiovascular risk scores, which were not independent predictors. Of the non-invasive indicators of fibrosis, the NAFLD fibrosis score was the only independent predictor of cardiovascular disease. Other histologic features, including steatohepatitis, were not associated with incident cardiovascular disease.In adults with biopsy-proven NAFLD, advanced fibrosis on biopsy and higher NAFLD fibrosis score were significant and independent predictors of incident cardiovascular disease, even after considering traditional risk factors and cardiovascular risk scores. These findings should be considered when evaluating NAFLD patients for primary prevention of cardiovascular disease, and further evaluation into the link between advanced fibrosis and cardiovascular disease is needed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Alimentary pharmacology & therapeutics

DOI

EISSN

1365-2036

ISSN

0269-2813

Publication Date

April 2020

Volume

51

Issue

7

Start / End Page

728 / 736

Related Subject Headings

  • Young Adult
  • Risk Factors
  • Prospective Studies
  • Non-alcoholic Fatty Liver Disease
  • Middle Aged
  • Massachusetts
  • Male
  • Liver Cirrhosis
  • Liver
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Henson, J. B., Simon, T. G., Kaplan, A., Osganian, S., Masia, R., & Corey, K. E. (2020). Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 51(7), 728–736. https://doi.org/10.1111/apt.15660
Henson, Jacqueline B., Tracey G. Simon, Alyson Kaplan, Stephanie Osganian, Ricard Masia, and Kathleen E. Corey. “Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.Alimentary Pharmacology & Therapeutics 51, no. 7 (April 2020): 728–36. https://doi.org/10.1111/apt.15660.
Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics. 2020 Apr;51(7):728–36.
Henson, Jacqueline B., et al. “Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.Alimentary Pharmacology & Therapeutics, vol. 51, no. 7, Apr. 2020, pp. 728–36. Epmc, doi:10.1111/apt.15660.
Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics. 2020 Apr;51(7):728–736.
Journal cover image

Published In

Alimentary pharmacology & therapeutics

DOI

EISSN

1365-2036

ISSN

0269-2813

Publication Date

April 2020

Volume

51

Issue

7

Start / End Page

728 / 736

Related Subject Headings

  • Young Adult
  • Risk Factors
  • Prospective Studies
  • Non-alcoholic Fatty Liver Disease
  • Middle Aged
  • Massachusetts
  • Male
  • Liver Cirrhosis
  • Liver
  • Humans